Stockskusumgar-limited IPO
Strong subscription, but fading GMP
Offer details
- Issue type
- Book-built Issue
- Listing on
- BSE, NSE
- Face value
- ₹1 Per Equity Share
- Lot size
- 1 share
- Min investment (retail)
- ₹14,665 · 35 shares
- Issue size
- Approx ₹650 Crores
- Issue window
- July 8, 2026 – July 10, 2026
Business overview
Kusumgar Limited's business details are not disclosed. The company's products, geography, and scale are not available in the given data. The company is going public with an IPO. No specific information is available about the company's operations.
Industry context
The industry context is not available due to lack of information about the company's business. The sector, tailwinds, headwinds, and competitive intensity are not disclosed. No comparison can be made with peers without this information.
Use of proceeds
The use of proceeds from the IPO is not disclosed in the available data. No information is available on how the company plans to utilize the funds.
Financials
Financial details such as revenue, EBITDA, and PAT trajectory and margins are not disclosed in the available data. No financial highlights can be discussed without this information.
Valuation
The valuation of the company at the upper band of the price range is not comparable to the sector without financial data. The P/E or P/B ratio cannot be determined.
Demand analysis (GMP + subscription)
The grey-market premium is Rs 158, which is a positive sign, but it has been fading over the last three days, indicating some cooling of demand. The subscription is 13.91x, which is a strong indication of demand. However, the fading GMP is a concern.
Risks
- Lack of information about the company's business
- Fading GMP
- IPO market volatility
Listing expectation
The listing-day outcome is uncertain due to the fading GMP. Investors should be cautious and consider holding or exiting depending on the listing price and market conditions.
Recommendation
Retail investors should exercise caution and consider watching the stock's performance after listing. HNIs may consider applying, but with a cautious approach due to the fading GMP. The listing-pop strategy is not recommended without a strong GMP and subscription.